BiotechTube

Pembrolizumab

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Carcinoma, Non-Small-Cell Lung

Conditions

Carcinoma, Non-Small-Cell Lung, Melanoma

Trial Timeline

Jan 31, 2019 → Aug 21, 2024

NCT ID
NCT03715205

About Pembrolizumab

Pembrolizumab is a approved stage product being developed by Merck for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT03715205. Target conditions include Carcinoma, Non-Small-Cell Lung, Melanoma.

What happened to similar drugs?

20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved

Approved (20) Terminated (2) Active (0)
✅Enfortumab VedotinAstellas PharmaApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT02083484Pre-clinicalCompleted
NCT07302347Phase 1/2Recruiting
NCT07089992Phase 2Recruiting
NCT07007273Phase 2Recruiting
NCT04569461Phase 2Withdrawn
NCT05815927Phase 3Recruiting
NCT05852223Phase 2Recruiting
NCT05879120Phase 2Withdrawn
NCT06004336Phase 2Recruiting
NCT05496036Phase 2Recruiting
NCT05131919Phase 2Active
NCT05197322Phase 2Recruiting
NCT05406713Phase 2Active
NCT05025813Phase 2Recruiting
NCT06413095Phase 1Completed
NCT05191472Phase 2Terminated
NCT05204160Phase 2Withdrawn
NCT04575961Phase 2Active
NCT04417166Phase 2Recruiting
NCT05188508Phase 2Recruiting

Competing Products

20 competing products in Carcinoma, Non-Small-Cell Lung

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
42
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
Cemiplimab + CetuximabEli LillyPhase 2
42
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
AzenosertibZentalis PharmaceuticalsPhase 2
25
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
35
LY2875358 + ErlotinibEli LillyPhase 2
35